ArticleJournal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer2026
Brief Report: Proposed Clinical Trial Guidelines Based on Clinicopathologic Heterogeneity of Metastatic Pulmonary Large Cell Neuroendocrine Carcinoma.
Article in Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
introductionPulmonary large cell neuroendocrine carcinoma (LCNEC) is a high-grade neuroendocrine carcinoma with clinical and molecular heterogeneity distinct from SCLC. This large retrospective series seeks to define the clinical outcomes for patients with newly diagnosed metastatic LCNEC and whether aligning treatment based on molecular classification improves outcomes.
methodsClinicopathologic data included demographics, treatment history, and immunohistochemical and genomic results. Patients with suspected transformed LCNEC (tLCNEC) underwent curated pathology review. Patient outcomes were assessed using Kaplan-Meier methodology.
resultsA total of 137 patients were included (100 with pure LCNEC and 37 with mixed histologies), of whom 15 had tLCNEC. For the 115 cases with genomic data available, 63 (55%) were classified as NSCLC like and 43 (37%) as SCLC like. The median overall survival (OS) from the start of first-line therapy was 10.0 months (95% confidence interval: 8.6-11.9) for patients with primary LCNEC and 16.3 months (9.4-40) for tLCNEC. There was no statistical difference in OS between patients treated with NSCLC or SCLC regimens (median OS: 12.1 mo [10.0-17.6] versus 9.4 mo [6.3-11.2]) or with the addition of immunotherapy to chemotherapy (median OS: 9.9 mo [7.7-13.9] versus 10.4 mo [8.6-14.1]). Several patients with tLCNEC who received local therapies for oligometastatic disease had long-term disease control.
conclusionsClinical outcomes for patients with LCNEC are poor, with no clear association of benefit observed through the application of molecularly classified standard treatments. Based on these data, we propose guidelines for the development of prospective trials of novel therapeutics aimed at addressing the unmet needs of this patient population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.